A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence - Trial NCT06336291
Access comprehensive clinical trial information for NCT06336291 through Pure Global AI's free database. This Phase 2 trial is sponsored by Philogen S.p.A. and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Philogen S.p.A.
Timeline & Enrollment
Phase 2
Jun 01, 2024
Jun 01, 2026
Primary Outcome
Adverse Events,Serious Adverse Events,Unacceptable Toxicity,DILI assessment,Survival
Summary
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and
 pharmacodynamic information of the combination of L19TNF and lomustine at different dose
 levels in patients with Glioblastoma at progression or recurrence
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06336291
Non-Device Trial